Molecular and infectivity studies of porcine circovirus in vaccines

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4745-4753

  McClenahan, Shasta D ^a   Krause, Philip R ^a   Uhlenhaut, Christine ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adventitious; Agents; Characterization; Circovirus; Porcine; Rotavirus; SafetyVaccine

Indexed keywords

NUCLEIC ACID; ROTAVIRUS VACCINE;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL CULTURE INFECTIVITY ASSAY; CIRCOVIRUS; CONTROLLED STUDY; GENE SEQUENCE; KIDNEY; NONHUMAN; PRIORITY JOURNAL; SWINE; TESTIS; VIRUS GENOME; VIRUS INACTIVATION; VIRUS INFECTIVITY;

EID: 79960647785     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.087     Document Type: Article

References (40)

1. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010;84(12):6033-40.
2. Tischer I, Rasch R, Tochtermann G. Characterization of papovavirus- and picornavirus-like particles in permanent pig kidney cell lines. Zentralbl Bakteriol Orig A 1974;226(2):153-67.
3. Tischer I, Gelderblom H, Vettermann W, Koch MA. A very small porcine virus with circular single-stranded DNA. Nature 1982;295(5844):64-6.
4. Raye W, Muhling J, Warfe L, Buddle JR, Palmer C, Wilcox GE. The detection of porcine circovirus in the Australian pig herd. Aust Vet J 2005;83(5):300-4.
5. Tischer I, Mields W, Wolff D, Vagt M, Griem W. Studies on epidemiology and pathogenicity of porcine circovirus. Arch Virol 1986;91(3-4):271-6.
6. Dulac GC, Afshar A. Porcine circovirus antigens in PK-15 cell line (ATCC CCL-33) and evidence of antibodies to circovirus in Canadian pigs. Can J Vet Res 1989;53(4):431-3.
7. Allan GM, McNeilly F, Cassidy JP, Reilly GA, Adair B, Ellis WA, et al. Pathogenesis of porcine circovirus: experimental infections of colostrum deprived piglets and examination of pig foetal material. Vet Microbiol 1995;44(1):49-64.
8. Krakowka S, Ellis JA, Meehan B, Kennedy S, McNeilly F, Allan G. Viral wasting syndrome of swine: experimental reproduction of postweaning multisystemic wasting syndrome in gnotobiotic swine by coinfection with porcine circovirus 2 and porcine parvovirus. Vet Pathol 2000;37(3):254-63.
9. Allan GM, McNeilly F, Kennedy S, Daft B, Clarke EG, Ellis JA, et al. Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe. J Vet Diagn Invest 1998;10(1):3-10.
10. Allan GM, Ellis JA. Porcine circoviruses: a review. J Vet Diagn Invest 2000;12(1):3-14.
11. Savic B, Milicevic V, Bojkovski J, Kureljusic B, Ivetic V, Pavlovic I. Detection rates of the swine torque teno viruses (TTVs), porcine circovirus type 2 (PCV2) and hepatitis E virus (HEV) in the livers of pigs with hepatitis. Vet Res Commun 2010;34(7):641-8.
12. Kim D, Ha Y, Oh Y, Chae C. Prevalence of porcine circovirus types 2a and b in pigs with and without post-weaning multi-systemic wasting syndrome. Vet J 2010.
13. Krakowka S, Ellis JA, McNeilly F, Ringler S, Rings DM, Allan G. Activation of the immune system is the pivotal event in the production of wasting disease in pigs infected with porcine circovirus-2 (PCV-2). Vet Pathol 2001;38(1):31-42.
14. Ladekjaer-Mikkelsen AS, Nielsen J, Stadejek T, Storgaard T, Krakowka S, Ellis J, et al. Reproduction of postweaning multisystemic wasting syndrome (PMWS) in immunostimulated and non-immunostimulated 3-week-old piglets experimentally infected with porcine circovirus type 2 (PCV2). Vet Microbiol 2002;89(2-3):97-114.
15. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-12):1-13.
16. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009;200(Suppl1):S9-15.
17. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010;201(11):1617-24.
18. Payne DC, Szilagyi PG, Staat MA, Edwards KM, Gentsch JR, Weinberg GA, et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J 2009;28(11):948-53.
19. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, Gomez-Altamirano CM, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010;362(4):299-305.
20. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11-22.
21. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33.
22. Brunborg IM, Moldal T, Jonassen CM. Quantitation of porcine circovirus type 2 isolated from serum/plasma and tissue samples of healthy pigs and pigs with postweaning multisystemic wasting syndrome using a TaqMan-based real-time PCR. J Virol Methods 2004;122(2):171-8.
23. Puvanendiran S, Stone S, Yu W, Johnson C, Garcia Jimenez L, Griggs T, et al. Differentiating PCV1 and PCV2 infections in swine; 2008. p. 131-6.
24. Cheung AK, Lager KM, Kohutyuk OI, Vincent AL, Henry SC, Baker RB, et al. Detection of two porcine circovirus type 2 genotypic groups in United States swine herds. Arch Virol 2007;152(5):1035-44.
25. Baylis SA, Finsterbusch T, Bannert N, Blumel J, Mankertz A. Analysis of porcine circovirus type 1 detected in Rotarix vaccine. Vaccine 2011;29(4):690-7.
26. Hattermann K, Roedner C, Schmitt C, Finsterbusch T, Steinfeldt T, Mankertz A. Infection studies on human cell lines with porcine circovirus type 1 and porcine circovirus type 2. Xenotransplantation 2004;11(3):284-94.
27. Shah K, Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 1976;103(1):1-12.
28. Sweet BH, Hilleman MR. The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med 1960;105:420-7.
29. Carroll-Pankhurst C, Engels EA, Strickler HD, Goedert JJ, Wagner J, Mortimer Jr EA. Thirty-five year mortality following receipt of SV40-contaminated polio vaccine during the neonatal period. Br J Cancer 2001;85(9):1295-7.
30. Olin P, Giesecke J. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand 1998;94:227-33.
31. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni Jr JF, Goedert JJ. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998;279(4):292-5.
32. Strickler HD, Goedert JJ. Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer-a review of the epidemiological evidence. Dev Biol Stand 1998;94:235-44.
33. Strickler HD. A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol Biomarkers Prev 2001;10(5):523-32.
34. Khan AS, Maudru T, Thompson A, Muller J, Sears JF, Peden KW. The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J Clin Virol 1998;11(1):7-18.
35. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications; 2010.
36. Onions D, Kolman J. Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010;38(3):377-80.
37. Li L, Kapoor A, Slikas B, Bamidele OS, Wang C, Shaukat S, et al. Multiple diverse circoviruses infect farm animals and are commonly found in human and chimpanzee feces. J Virol 2010;84(4):1674-82.
38. Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006;32(3): 258-63.
39. FDA. Update on recommendations for the use of rotavirus vaccines. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm212140.htm.
40. Kuehn BM. FDA: benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010;304(1):30-1.